Table of contents
September 2006 Volume 3 No 9
Editorial
Viewpoints
An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated
454There is considerable controversy regarding the role of extended pelvic lymph-node dissection (PLND) during radical prostatectomy. In the first of a pair of articles discussing this issue, Burkhard et al. speculate on the potential therapeutic benefit of extended PLND, and argue that it should be performed in the majority of patients undergoing radical prostatectomy.
The case against extended lymph-node dissection for prostate cancer
456In our second article discussing the role of extended pelvic lymph-node dissection (PLND) during radical prostatectomy, Hartwig Huland argues that extended PLND is not justified in presently selected patients, is rarely used to guide intraoperative decisions, and has little impact on treatment outcomes.
Research Highlights
Intralesional IFN-
2b benefits men with Peyronie's disease
458doi:10.1038/ncpuro0565 | Full Text | PDF (103K)
Leak-point pressure might identify the predominant symptom in mixed incontinence
458Pomegranate juice might delay recurrence of prostate cancer
458doi:10.1038/ncpuro0567 | Full Text | PDF (100K)
New immunotherapy agent prolongs survival of men with advanced prostate cancer
459doi:10.1038/ncpuro0568 | Full Text | PDF (103K)
Condom catheters are recommended for men without dementia
459Pediatric detrusor overactivity can be treated with botulinum A toxin
460doi:10.1038/ncpuro0570 | Full Text | PDF (102K)
Does Viagra® improve lower urinary tract symptoms in men with erectile dysfunction?
460Immediate androgen deprivation treatment beneficial in men with aggressive prostate cancer
461The urologist is a key determinant of ADT use in men with prostate cancer
461doi:10.1038/ncpuro0572 | Full Text | PDF (112K)
Does cathelicidin have a role in the immune protection of the urinary tract?
461Formalin instillation to treat hemorrhagic radiation proctopathy
462IMP3: a new prognostic biomarker for renal-cell carcinoma?
462doi:10.1038/ncponc0576 | Full Text | PDF (101K)
Testosterone therapy rebuilds muscle in older men
463doi:10.1038/ncpendmet0248 | Full Text | PDF (102K)
Practice Points
Can PSA nadir predict prostate cancer outcomes following radiotherapy?
464doi:10.1038/ncpuro0564 | Full Text | PDF (100K)
Safety and durability of dextranomer injections for urinary incontinence
466Does saturation biopsy improve prostate cancer detection?
468The role of hormone replacement therapy in healthy elderly men
470A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer
472Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out
474Reviews
Treatment for renal cancer: are we beyond the cytokine era?
478Small molecule inhibitors target growth-receptor signaling, cell-cycle regulation and angiogenesis, and have been the subject of much interest for their potential in treating patients with renal cancer. Although data reported at the 2006 ASCO Annual Meeting have provided further evidence of their potential, it is important that cytokine-based therapies are not forgotten. This review examines the different treatment options for patients with renal cancer.
doi:10.1038/ncpuro0581 | Full Text | PDF (156K)
The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer
485Lymph node dissection conducted during radical cystectomy is essential for tumor staging in patients with invasive bladder cancer. It might also provide therapeutic benefits for these patients and is, therefore, considered an important part of surgical management. In this Review, the authors discuss standard and extended lymph node dissection in patients with bladder cancer.
doi:10.1038/ncpuro0582 | Full Text | PDF (185K)
Drug Insight: 5-reductase inhibitors for the treatment of benign prostatic hyperplasia
495There are a number of treatments available for men with BPH, but 5
-reductase inhibitors are the only medical treatment that can prevent BPH progression and avoid the need for surgery. This Drug Insight Review discusses the 5-reductase inhibitors finasteride and dutasteride, their efficacy, mechanisms of action and use in men with BPH.
doi:10.1038/ncpuro0577 | Full Text | PDF (192K)
Case Study
Leiomyoma of the epididymis treated with partial epididymectomy
504doi:10.1038/ncpuro0578 | Full Text | PDF (277K)
